Molecular Partners AG - Special Call Transcript
Ladies and gentlemen, welcome to the Molecular Partners conference call regarding the FDA decision of abicipar. I am Sandra, the Chorus Call operator. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Thomas Schneckenburger, Investor Relations. Please go ahead, sir.
Thanks, Sandra. Good morning, ladies and gentlemen. Welcome, everybody, to this conference call in relation to the joint news release which we have just published together with our partner, Allergan, regarding the FDA decision on the BLA for abicipar.
With me here in the room in Schlieren are: Patrick Amstutz, the CEO of Molecular Partners; Andreas Emmenegger, the Chief Financial Officer; and Michael Stumpp, the COO of the company. Moreover, on the phone, in the U.S., we have also Seth Lewis, our SVP, IR, Comms and Strategy. Patrick will start this call with a few opening remarks before we will move over to take your questions. Before starting, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
